Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Avaliação Justa
O PE mais recente da empresa é -8.70, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 18.21M ações, uma redução de 7.22% em relação ao trimestre anterior.
Mantido por ETHSX
O Super Investidor ETHSX possui 46.95K ações desta empresa.
Baixa Atividade de Mercado
A empresa tem menor interesse dos investidores, com uma taxa de giro de 20 dias de 0.10.